Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
oleh: José Medina-Echeverz, Maria Hinterberger, Marco Testori, Marlene Geiger, Raphael Giessel, Barbara Bathke, Ronny Kassub, Fabienne Gräbnitz, Giovanna Fiore, Sonia T. Wennier, Paul Chaplin, Mark Suter, Hubertus Hochrein, Henning Lauterbach
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2019-11-01 |
Deskripsi
CD40 agonists have been investigated as a strategy to awaken the immune system against cancers. Here, the authors use a virus encoding CD40L and tumour-associated antigens to enhance innate and adaptive immunity that together with tumour targeting antibodies controls the growth of tumours in mice.